San Diego, CA -- (SBWire) -- 04/15/2013 --A substantial stock price drop in late last year prompted an ongoing investigation on behalf of investors in NASDAQ:ONTY shares concerning whether certain Oncothyreon Inc directors and officers breached their fiduciary duties owed to stockholders in connection certain statements.
Investors who purchased shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Oncothyreon’s officers and directors breached their fiduciary duties and caused damage to the company and its shareholders by, among other things, failing to implement adequate internal controls.
On Dec. 19, 2012, Oncothyreon announced that L-BLP25 (Stimuvax®) did not meet primary endpoint of improvement in overall survival in pivotal Phase 3 Trial in patients with non-small cell lung cancer.
Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY) dropped from $4.50 on Dec. 18, 2012, to as low as $1.84 on Dec. 28, 2012.
On April 12, 2013, NASDAQ:ONTY shares closed at $2.34 per share, which is significantly below its current 52 week High of $6.24 per share.
Those who purchased shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), you have certain options and you should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
NASDAQ:ONTY Investor Alert: Investigation of Oncothyreon Inc Announced
An investigation for long-term investors in NASDAQ:ONTY shares over potential wrongdoing at Oncothyreon Inc was announced and current long-term NASDAQ:ONTY stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com